
CLAIMS

1. A compound represented by


(1) the formula (I):



(I)

or

(2) the formula (II):



(II)

wherein

R^1 is a C_{1-6} alkyl group;

R^2 is

~~(1) a C_{1-6} alkyl group optionally having 1 to 3 substituents selected from~~

~~(a) a hydroxy group,~~

~~(b) a halogen atom,~~

~~(c) a C_{1-6} alkoxy group,~~

~~(d) a C_{1-6} alkyl-carbonyloxy group,~~

~~(e) a 4- to 10-membered monocyclic aromatic heterocyclic group~~

optionally having 1 to 3 halogen atoms,

(f) a C_{3-10} cycloalkyl group, and

(g) pyrrolidinyl, piperidino, morpholino, thiomorpholino, piperazinyl, imidazolidin-1-yl and pyrazolidin-1-yl, each of which is optionally having an oxo group,

(2) a 3- to 10-membered heterocyclic group optionally having 1 to 3 substituents selected from a C_{1-6} alkyl group and an oxo group,

(3) a carboxy group,

(4) a C_{1-6} alkoxy-carbonyl group optionally having 1 to 3 substituents selected from a 3- to 10-membered monocyclic non-aromatic heterocyclic group optionally having 1 to 3 substituents selected from a C_{1-6} alkyl group and oxo group,

(5) a C_{1-6} alkyl-carbonyl group, or

(6) a group represented by the formula: -CO-NR'R" wherein R' and R" are each a hydrogen atom, or R' and R" form, together with the nitrogen atom bonded thereto, a 4- to 7-membered nonaromatic nitrogen-containing heterocycle containing, as a ring-constituting atom besides carbon atom, one nitrogen atom, and optionally further containing 1 or 2 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom optionally having 1 to 3 substituents selected from halogen atom(s);

X is

(1) a hydrogen atom;

(2) a C_{1-6} alkyl group optionally substituted by 1 to 3 substituents selected from

(a) a halogen atom,

~~(b) a hydroxy group,~~

(~~c~~a) a C_{1-6} alkoxy group optionally having a C_{1-6} alkoxy group ~~or a halogen atom~~, and

~~(d) a C_{1-6} alkylthio group,~~

~~(e) a C_{6-14} aryl group,~~

(~~f~~b) a C_{6-14} aryloxy group ~~optionally having a C_{1-6} alkoxy group or a halogen atom, and~~

~~(g) a 4- to 10-membered monocyclic aromatic heterocyclic group; or~~

~~(3) a C_{3-10} cycloalkyl group~~; and


ring A is

(1)

triazole optionally further having ~~1 to 5~~ substituent(s) selected from a C_{6-10} aryl group optionally having halogen atom(s) ~~substituent group A~~,

(2) imidazo[1,2-a]pyridine ~~optionally further having 1 to 5 substituents selected from substituent group A~~, or

(3) a ring represented by



wherein R^a and R^b are each independently a hydrogen atom, a halogen atom, or a C_{1-6} alkoxy group~~, or a C_{1-6} alkoxy-carbonyl group~~, and at least one of R^a and R^b is not a hydrogen atom; and Y^1 is N, and Y^2 is CH;

R^3 is

~~(1) a C_{1-6} alkoxy group optionally substituted by a C_{1-6} alkoxy group or a halogen atom,~~

~~(2) a C_{1-6} alkylthio group,~~

~~(3) a C_{3-10} cycloalkyl group optionally substituted by a C_{1-6} alkyl group,~~

~~(4) a C_{6-14} aryl group, or~~

~~(5) a 4- to 10-membered monocyclic aromatic heterocyclic group optionally substituted by a C_{1-6} alkyl group~~

;

X^1 is a C_{1-6} alkylene group;


ring A^1 is

(1) imidazo[1,2-a]pyridine ~~optionally further having 1 to 5 substituents selected from substituent group A~~,


~~(2) indole optionally further having 1 to 5 substituents selected from substituent group A,~~ or

(~~3~~2) benzimidazole ~~optionally~~ further having ~~1 to 5~~ substituent(s) selected from a halogen atom and a C_{1-6} alkoxy group~~substituent group A~~; and

the group represented by the formula:



is a group represented by the formula:



wherein R^4 is

~~(1) a hydrogen atom,~~

~~(2) a cyano group,~~

~~(3) a C_{1-6} alkyl group optionally having 1 to 3 substituents selected from~~

~~(a) a hydroxy group,~~

~~(b) a C_{1-6} alkoxy group,~~

~~(c) a C_{1-6} alkyl-carbonyloxy group,~~

~~(d) a 4- to 10-membered monocyclic aromatic heterocyclic group optionally having 1 to 3 halogen atoms,~~

~~(e) a C_{3-10} cycloalkyl group, and~~

~~(f) pyrrolidinyl, piperidino, morpholino, thiomorpholino, piperazinyl, imidazolidin-1-yl and pyrazolidin-1-yl, each of which is optionally having an oxo group,~~

~~(4) a 3- to 10-membered heterocyclic group optionally having 1 to 3 substituents selected from a C_{1-6} alkyl group and an oxo group,~~

~~(5) a carboxy group,~~

~~(6) a C_{1-6} alkoxy-carbonyl group optionally having 1 to 3 substituents selected from a 3- to 10-membered monocyclic non-aromatic heterocyclic group optionally having 1 to 3 substituents selected from a C_{1-6} alkyl group and oxo group, or~~

~~(7)~~ a group represented by the formula: -CO-NR'R" wherein ~~R' and R" are each a hydrogen atom, or~~ R' and R" form, together with the nitrogen atom bonded thereto, a 4- to 7-membered nonaromatic nitrogen-containing heterocycle containing, as a ring-constituting atom besides carbon atom, one nitrogen atom, and optionally further containing 1 or 2 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom ~~optionally having 1 to 3 substituents selected from halogen atom(s);~~

~~the substituent group A consists of~~

~~(1) a halogen atom;~~

~~(2) a nitro group;~~

~~(3) a cyano group;~~

~~(4) a hydroxy group;~~

~~(5) a C_{1-6} alkoxy group optionally having 1 to 5 substituents selected from substituent group B;~~

~~(6) an amino group optionally having 1 or 2 substituents selected from substituent group B;~~

~~(7) oxo group;~~

~~(8) thioxo group;~~

(9) a mercapto group optionally having a substituent selected from substituent group B (the mercapto group is optionally oxidized);

(10) a C_{1-4} alkylenedioxy group;

(11) a C_{1-6} alkyl group optionally having 1 to 5 substituents selected from substituent group B;

(12) a C_{7-16} aralkyl group;

(13) a 3- to 10-membered cyclic hydrocarbon group optionally having 1 to 5 substituents selected from substituent group B; and

(14) a 3- to 10-membered heterocyclic group optionally having 1 to 5 substituents selected from substituent group B; and

the substituent group B consists of

(1) a halogen atom;

(2) a nitro group;

(3) a cyano group;

(4) a hydroxy group;

(5) a C_{1-6} alkoxy group optionally having 1 to 3 halogen atoms;

(6) an amino group;

(7) a mono- or di-C_{1-6} alkylamino group;

(8) a C_{7-16} aralkylamino group;

(9) a C_{1-6} alkoxy-carbonylamino group;

(10) a C_{1-6} alkyl-carbonylamino group;

(11) a C_{1-6} alkyl-carbonyloxy group;

(12) a C_{1-6} alkyl-carbonyl group;

(13) a carboxy group;

(14) a C_{1-6} alkoxy-carbonyl group;

(15) a carbamoyl group;

(16) a mono- or di-C_{1-6} alkylcarbamoyl group;

(17) oxo group;

(18) thioxo group;

(19) a mercapto group;

(20) a C_{1-6} alkylthio group;

(21) a C_{1-6} alkylsulfinyl group;

(22) a C_{1-6} alkylsulfonyl group;

(23) a C_{1-4} alkylenedioxy group;

~~(24) a C_{1-6} alkyl group optionally having 1 to 3 substituents selected from~~

~~(a) a halogen atom,~~

~~(b) a hydroxy group,~~

~~(c) a C_{1-6} alkoxy group,~~

~~(d) a C_{6-14} aryl group,~~

~~(e) an amino group,~~

~~(f) a mono- or di-C_{1-6} alkylamino group,~~

~~(g) a C_{7-16} aralkylamino group, and~~

~~(h) a C_{1-6} alkoxy-carbonylamino group;~~

~~(25) a C_{6-14} aryl group optionally having 1 to 3 halogen atoms;~~

~~(26) a 4- to 10-membered monocyclic aromatic heterocyclic group optionally having 1 to 3 halogen atoms ;~~

~~(27) a 3- to 10-membered monocyclic non-aromatic heterocyclic group optionally having 1 to 3 substituents selected from a C_{1-6} alkyl group and an oxo group;~~


~~(28) a C_{7-16} aralkyl group;~~

~~(29) a C_{3-10} cycloalkyl group; and~~


~~(30) pyrrolidinyl, piperidino, morpholino, thiomorpholino, piperazinyl, imidazolidin-1-yl and pyrazolidin-1-yl, each of which is optionally having an oxo group~~,

or a salt thereof.

2. The compound or salt of claim 1, wherein the group represented by the formula:



is a group represented by the formula:



wherein R^4 is

~~(1) a cyano group,~~

~~(2) a C_{1-6} alkyl group optionally having 1 to 3 substituents selected from~~

~~(a) a hydroxy group,~~

~~(b) a C_{1-6} alkoxy group,~~

~~(c) a C_{1-6} alkyl-carbonyloxy group,~~

~~(d) a 4- to 10-membered monocyclic aromatic heterocyclic group optionally having 1 to 3 halogen atoms,~~

~~(e) a C_{3-10} cycloalkyl group, and~~

~~(f) pyrrolidinyl, piperidino, morpholino, thiomorpholino, piperazinyl, imidazolidin-1-yl and pyrazolidin-1-yl, each of which is optionally having an oxo group,~~


~~(3) a 3- to 10-membered heterocyclic group optionally having 1 to 3 substituents selected from a C_{1-6} alkyl group and an oxo group,~~

~~(4) a carboxy group,~~


~~(5) a C_{1-6} alkoxy-carbonyl group optionally having 1 to 3 substituents selected from a 3- to 10-membered monocyclic non-aromatic heterocyclic group optionally having 1 to 3 substituents selected from a C_{1-6} alkyl group and an oxo group or~~

~~(6)~~ a group represented by the formula: -CO-NR'R" wherein ~~R' and R" are each a hydrogen atom, or~~ R' and R" form, together with the nitrogen atom bonded thereto, a 4- to 7-membered nonaromatic nitrogen-containing heterocycle containing, as a ring-constituting atom besides carbon atom, one nitrogen atom, and optionally further containing 1 or 2 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom ~~optionally having 1 to 3 substituents selected from halogen atom(s)~~.

~~3. The compound of claim 1, wherein the group represented by the formula:~~



~~is a group represented by the formula:~~



~~wherein R^4 is a group represented by the formula: -CO-NR'R" wherein R' and R" are each a hydrogen atom, or R' and R" form, together with the nitrogen atom bonded thereto, a 4- to 7-membered nonaromatic nitrogen-containing heterocycle optionally having 1 to 3 substituents selected from halogen atom(s).~~

4. The compound of claim 1, wherein R" is

(1) a carboxy group,

(2) a C_{1-6} alkoxy-carbonyl group optionally having 1 to 3 substituents selected from a 3- to 10-membered monocyclic non-aromatic heterocyclic group optionally having 1 to 3 substituents selected from a C_{1-6} alkyl group and oxo group,

(3) a C_{1-6} alkyl-carbonyl group, or

(4) a group represented by the formula: -CO-NR'R" wherein R' and R" are each a hydrogen atom, or R' and R" form, together with the nitrogen atom bonded thereto, a 4- to 7-membered nonaromatic nitrogen-containing heterocycle optionally having 1 to 3 substituents selected from halogen atom(s).

~~5~~3. The compound or salt of claim 1, wherein X is a C_{1-6} alkyl group optionally substituted by a C_{1-6} alkoxy group.

~~6. The compound of claim 1, wherein R^3 is a C_{1-6} alkoxy group optionally substituted by a C_{1-6} alkoxy group or a halogen atom.~~

~~7~~4. The compound or salt of claim 1, which is 1-(2-fluorophenyl)-5-(4-methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1H-1,2,3-triazole-4-carboxamide or a salt thereof.

~~8~~5. A medicament comprising the compound or salt of claim 1~~, or a salt thereof~~ as an active ingredient.

~~9~~6. The medicament of claim ~~8~~5, which is a renin inhibitor.

~~10~~7. The medicament of claim ~~8~~5, which is a prophylactic or therapeutic agent of a circulatory disease.


~~11~~8. The medicament of claim ~~8~~5, which is a prophylactic or therapeutic agent of hypertension and/or various organ damages attributable to hypertension.

~~12. Use of the compound of claim 1 or a salt thereof for the production of a prophylactic or therapeutic agent for a circulatory disease.~~

~~13. Use of the compound of claim 12, which is for the production of a prophylactic or therapeutic agent for~~

~~hypertension and/or various organ damages attributable to hypertension.~~

~~149~~. Use of the compound or salt of claim ~~121, which is~~



for the production of a prophylactic or therapeutic agent for blood pressure circadian rhythm abnormality, acute heart failure~~heart disease~~, progression of cardiac insufficiency after myocardial infarction, or renal disease in medicine.

~~15. Use of the compound of claim 14, wherein the heart disease is acute heart failure.~~

~~16~~10. Use of ~~the compound of~~ claim ~~14~~9, wherein the renal disease is renal failure.